参考文献/References:
[1]. Lubrano V, Balzan S. Consolidated and emerging inflammatory markers in coronary artery disease[J]. World J Exp Med, 2015,5(1):21-32.
[2]. Ghattas A,Griffiths HR,Devitt A, et al. Monocytes in coronary artery disease and atherosclerosis:where are we now?[J]. J Am Coll Cardiol, 2013, 62(17):1541-1551.
[3]. Riwanto M, Landmesser U. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease.[J]. J Lipid Res, 2013, 54(12):3227-3243.
[4]. Kanbay M, Solak Y, Unal HU, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease[J]. Int Urol Nephrol, 2014, 46(8):1619-1625.
[5]. Kundi H, Kiziltunc E, Cetin M, et al. Association of monocyte/HDL-C ratio with SYNTAX scores in patients with stable coronary artery disease [J].Herz, 2016,41(6):523-529.
[6]. ?i?ek G, Kundi H, Bozbay M, et al. The relationship between admission monocyte HDL-C ratio with short-term and long-term mortality among STEMI patients treated with successful primary PCI [J].Coron Artery Dis, 2016,27(3):176-184.
[7]. Karata ? MB, ?anga Y, ?zcan KS, et al. Monocyte to high-density lipoprotein ratio as a new prognostic marker in patients with STEMI undergoing primary percutaneous coronary intervention[J]. Am J Emerg Med, 2016, 34(2):240-244.
[8]. Cetin MS, Ozcan Cetin EH, Kalender E, et al. Monocyte to HDL cholesterol ratio predicts coronary artery disease severity and future major c ardiovascular adverse events in acute coronary syndrome[J]. Heart Lung Circ,2016,25(11):1077-1086.
[9]. A? ?kg?z SK, A??kg?z E, ?ensoy B, et al. Monocyte to high-density lipoprotein cholesterol ratio is predictive of in-hospital and five-year mortality in ST-segment elevation myocardial infarction[J]. Cardiol J, 2016, 23(5):505-512.
[10]. 毛琦,项朝君,王玉清,等. 单核细胞与高密度脂蛋白胆固醇的比值影响非ST段抬高型急性冠脉综合征预后[J]. 第三军医大学学报, 2019,41(5):62-68.
[11]. Vrints CJ. Pathophysiology of the no-reflow phenomenon[J]. Acute Cardiac Care,2009,11(2):69-76.
[12]. C anpolat U, ?etin EH, Cetin S, et al. Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation[J]. Clin Appl Thromb Hemost,2016,22(5):476-482.
[13]. Balta S, Celik T, Ozturk C, et al. The relation between monocyte to HDL ratio and no-reflow phenomenon in the patients with acute ST-segment elevation myocardial infarcti on.[J]. Am J Emerg Med, 2016, 34(8):1542-1547.
[14]. Sousa-Uva M,Neumann FJ,Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization[J].EuroIntervention,2019,14(14):1435-1534.
[15]. Kim MS, Dean LS. In-stent restenosis[J]. Cardiovasc Ther, 2011, 29(3):190-198.
[16]. Cetin EH, Cetin MS, Canpolat U, et al. Monocyte/HDL-cholesterol ratio predicts the definite stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myoca rdial infarction[J]. Biomark Med, 2015, 9(10):967-977.
[17]. Ucar FM. A potential marker of bare metal stent restenosis: monocyte count - to- HDL cholesterol ratio[J]. BMC Cardiovasc Disord, 2016, 16(1):186.
[18]. Yilmaz S, Akboga MK, Sen F, et al. Usefulness of the monocyte-to-high-density lipoprotein cholesterol ratio to predict bare metal stent restenosis[J]. Biomark Med,2016,10(9):959-966.
[19]. Yuan Y, Qiu H, Hu X, et al. Predictive value of inflammatory factors on contrast-induced acute kidney injury in patients who under went an emergency percutaneous coronary intervention[J]. Clin Cardiol,2017,40(9):719-725.
[20]. Sun XP, Li J, Zhu WW, et al. Platelet to lymphocyte ratio predicts contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Angiology, 2017,55(1):132-138.
[21]. Sa ? S, Y ?ld?z A, Aydin Kaderli A, et al. Association of monocyte to HDL cholesterol level with contrast induced nephropathy in STEMI patients treated with primary PCI[J]. Clin Chem Lab Med,2017,55(1):132-138.
[22]. Ulus T, Isgandarov K, Yilmaz AS, et al. Monocyte to high-density lipoprotein ratio predicts contrast-induced nephropathy in patients with acute coronary syndrome[J]. Angiology, 2018,69(10):909-916.
[23]. Dogan A, Oylumlu M. Increased monocyte-to-HDL cholesterol ratio is related to cardiac syndrome X[J]. Acta Cardiologica, 2016, 117(5):S47-S47.
[24]. 乔树宾,崔锦钢,蒋晓威,等.冠状动脉扩张症的新分型及临床意义[J].中华心血管病杂志, 2018, 46(10):756.
[25]. Gr?nke S,Erdmann E.Coronary artery ectasia[J]. Clin Res Cardiol, 2007, 96(11):831.
[26]. Kundi H,Gok M,Kiziltunc E,et al.Relation between monocyte to high-density lipoprotein cholesterol ratio with presence and severity of isolated coronary artery ectasia[J]. Am J Cardiol, 2015, 116(11):1685-1689.
[27]. Enhos A,Cosansu K,Huyut MA,et al.Assessment of the relationship between monocyte to high-density lipoprotein ratio and myocardial bridge[J].Arq Bras Cardiol,2019,112(1):12-17.
[28]. Yayla KG,Canpolat U,Yayla ?, et al. A novel marker of impaired aortic elasticity in never treated hypertensive patients:monocyte/high-density lipoprotein cholesterol ratio[J]. Acta Cardiologica Sinica, 2017, 33(1):41-49.
[29]. Aydin E, Ates I, Fettah Arikan M, et al. The ratio of monocyte frequency to HDL cholesterol level as a predictor of asymptomatic organ damage in patients with prima ry hypertension[J]. Hypertens Res, 2017,40(8),758-764.
[30]. Kim JB, Hama S, Hough G, et al. Heart failure is associated with impaired anti-inflammatory and antioxidant properties of high-density lipoproteins[J]. Am J Cardiol, 2013, 112(11):1770-1777.
[31]. Moro-García MA,Echeverría A,Galán-Artímez MC,et al. Immunosenescence and inflammation characterize chronic heart failure patients with more advanced disease[J]. Int J Cardiol, 2014,174(3):590-599.
[32]. 周琼,张洁钰,张菲斐.糖尿病合并射血分数保留心力衰竭患者单核细胞/高密度脂蛋白胆固醇比率与N末端B型利钠肽原水平相关性[J].中国医药导报, 2017,14(5):55-58.
[33]. Suzuki A, Fukuzawa K, Yamashita T, et al. Monocyte-to-HDL-cholesterol ratio and left atrial remodelling in atrial fibrillation:author’s reply[J]. Europace, 2017,19(8):1409-1410.
[34]. Canpolat U,Aytemir K,Yorgun H,et al.The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation[J].Europace,2015,17(12): 1807-1815.
[35]. Saskin H,Serhan Ozcan K,Yilmaz S.High preoperative monocyte count/high-density lipoprotein ratio is associated with postoperative atrial fibrillation and mortality in coronary artery bypass grafting[J] .Interact Cardiovasc Thorac Surg,2017,24(3):395-401.
[36]. Satilmis S.Role of the monocyte-to-high-density lipoprotein ratio in predicting atrial high-rate episodes detected by cardiac implantable el ectronic devices[J]. North Clin Istanb,2018,5(2):96-101.
[37]. Demir V, Samet Y, Akboga MK. Association of lymphocyte-monocyte ratio and monocyte-to-high-density lipoprotein ratio with the presence and severity of rheumatic mitral valve stenosis[J]. Biomark Med ,2017,11(8):657-663.
[38]. Wei XB,Chen F,Huang JL,et al.Novel risk biomarker for infective endocarditis patients with normal left ventricular ejection fraction- monocyte to high-density lipoprotein cholesterol ratio[J]. Circ J, 2017, 82(1):283-288.
[39]. 陈伟伟,高润霖,刘力生,等.《中国心血管病报告2017》概要.中国循环杂志,2018, 33(1):1-8.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(7):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(7):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[7]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(7):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[8]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(7):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[9]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(7):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
[10]李海威 姜红 李宪伦.射血分数保留性心力衰竭患者运动康复的研究进展[J].心血管病学进展,2019,(8):1146.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.019]
LI Haiwei,JIANG Hong,LI Xianlun.Exercise Rehabilitation in Patients with Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2019,(7):1146.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.019]